$24.43
-1.14-4.46%
Last update: Nov 10, 5:59 PM
Caris Life Sciences Inc
CAINASDAQ
Caris Life Sciences rose 3.1% from $24.80 to $25.57, behind the S&P 500's +10.0%. Its worst day was Nov 5 (−21.6%), and its low came May 15 at $14.55.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.28 beat the $0.07 estimate on $292.9M revenue (est. $280.9M); FY revenue guidance of $1.0B–$1.0B against the $995.8M consensus.
+4.7% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
EPS of $0.00 beat the $-0.02 estimate on $216.2M revenue (est. $209.5M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
−18.6% · S&P 500 +0.8%
Caris Life Sciences shares rose 11.6%, while the S&P 500 rose 0.4%.
+11.6% · S&P 500 +0.4%
EPS of $0.00 missed the $0.01 estimate on $263.7M revenue (est. $237.0M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
+21.6%, the year's best day · S&P 500 −0.2%
EPS of $0.05 beat the $0.02 estimate on $275.4M revenue (est. $254.4M); FY revenue guidance of $1.0B–$1.1B against the $1.0B consensus.
−21.6%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $25.57 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.10, revenue est. $288.6M).
Nothing in the past 12 months.
All CAI dividend historyAs of the Nov 9, 2026 close
Replay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CAI and SPY from Benzinga historical bars. Not investment advice.
